Norwood Abbey raises $4.13 million
10 September, 2002 by Melissa TrudingerNorwood Abbey has raised $4.13 million in a placement to institutional and professional investors.
Solbec hires Bioscience to grow anti-cancer ingredient
10 September, 2002 by Melissa TrudingerWestern Australian horticulture company Bioscience has been commissioned by Solbec Pharmaceuticals to set up and run Solbec's horticultural production facility, used to produce its lead anti-cancer compound from Solanum linnaeanum, or devil's apple.
Lucre for Bioglobal's LuciLure
10 September, 2002 by Melissa TrudingerBioglobal has signed an exclusive three-year agreement to market and distribute its LuciLure blowfly trap for sheep protection and landfill markets in Australia and New Zealand.
Novogen claims success in heart drug trial
10 September, 2002 by Graeme O'NeillSydney pharmaceutical company Novogen says the first human clinical trial of its candidate heart-disease therapeutic NV-04 has confirmed the "outstanding potency" it showed in initial trials in laboratory animals.
Meditech teams up to market skin cancer treatment
10 September, 2002 by Graeme O'NeillMeditech Research and SkyePharma have completed a commercial pas-de-deux that sees them divide up the Pacific Rim markets for the Solarase, a topical treatment for the pre-cancerous skin condition, actinic or solar keratosis.
UK calls for GM animal advisory body
10 September, 2002 by Melissa TrudingerThe UK's Agriculture and Environment Biotechnology Commission has called for a new advisory body and development of a strategy to deal with issues relating to genetically modified and cloned animals.
Bionomics touts new mouse model, posts loss
09 September, 2002 by Melissa TrudingerA mouse model for inherited epilepsy has been created by Adelaide company Bionomics by 'knocking-in' the human mutation. The model exhibits seizures similar to human epileptic seizures.
Autogen wins US patent for Beacon gene
09 September, 2002 by Melissa TrudingerMelbourne biotech Autogen has been granted a US patent for its Beacon gene, and its use as a therapeutic or diagnostic in conditions like obesity, diabetes and energy imbalance.
Interview: the antisense evangelist
06 September, 2002 by Melissa TrudingerPersistence has paid off for Stanley Crooke and his company Isis Pharmaceuticals.
AusBiotech recruiting for French devices and diagnostics tour
05 September, 2002 by Iain ScottUp to 20 AusBiotech members are being offered the chance to take part in a medical devices and diagnostics mission in France this November 4-8, under the auspices of the French-Australian Industrial Research (FAIR) program.
Chemeq picks up the pace in South Africa
05 September, 2002 by Melissa TrudingerPerth-based company Chemeq has started its push to introduce its polymeric antimicrobial drug for prevention of colibacillosis in pigs into South Africa, the first country to approve the veterinary product.
MSAC decision disappoints Sirtex CEO
04 September, 2002 by David BinningThe chief executive of Sydney-based company Sirtex has expressed disappointment with the Medical Services Advisory Committee (MSAC) following its surprise rejection of a subsidy application for the company's liver cancer treatment.
Virax to extend trials for HIV/AIDS therapy
03 September, 2002 by Melissa TrudingerMelbourne-based immune therapies company Virax Holdings has announced an extension to its Phase I/IIA clinical trial to further assess the potential of its HIV/AIDS therapy.
GroPep names new CEO
02 September, 2002 by Iain ScottAdelaide-based biotech GroPep has named former Faulding Pharmaceuticals top brass Robert Finder as its new CEO.
Auspep aiming to ride the big waves
29 August, 2002 by Pete YoungAustralian peptide maker Auspep is looking for funds to finance its growth on the back of a market that is jagging upward.
